| Dr Kenneth L Harris, MD | |
|
2375 Champions Blvd, Auburn, AL 36830-6471 | |
| (334) 745-6447 | |
| (334) 742-0713 |
| Full Name | Dr Kenneth L Harris |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 34 Years |
| Location | 2375 Champions Blvd, Auburn, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881634475 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 15999 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| East Alabama Medical Center And Snf | Opelika, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lee Obstetrics And Gynecology, Pc | 4880614270 | 11 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.
The lining of the intestine is the most rapidly-renewing tissue in the body. Routine shedding of epithelial cells from this lining is a key element of tissue turnover, and is thus essential to maintaining optimal health. Altered shedding is associated with multiple disorders, ranging from inflammatory bowel disease (IBD) to colorectal cancer.
› Verified 5 days ago
| Entity Name | The East Alabama Health Care Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073685483 PECOS PAC ID: 3072403237 Enrollment ID: O20040824001092 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.
The lining of the intestine is the most rapidly-renewing tissue in the body. Routine shedding of epithelial cells from this lining is a key element of tissue turnover, and is thus essential to maintaining optimal health. Altered shedding is associated with multiple disorders, ranging from inflammatory bowel disease (IBD) to colorectal cancer.
› Verified 5 days ago
| Entity Name | Lee Obstetrics & Gynecology, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033170238 PECOS PAC ID: 4880614270 Enrollment ID: O20051130000482 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.
The lining of the intestine is the most rapidly-renewing tissue in the body. Routine shedding of epithelial cells from this lining is a key element of tissue turnover, and is thus essential to maintaining optimal health. Altered shedding is associated with multiple disorders, ranging from inflammatory bowel disease (IBD) to colorectal cancer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kenneth L Harris, MD 2375 Champions Blvd, Auburn, AL 36830-6471 Ph: (334) 745-6447 | Dr Kenneth L Harris, MD 2375 Champions Blvd, Auburn, AL 36830-6471 Ph: (334) 745-6447 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.
The lining of the intestine is the most rapidly-renewing tissue in the body. Routine shedding of epithelial cells from this lining is a key element of tissue turnover, and is thus essential to maintaining optimal health. Altered shedding is associated with multiple disorders, ranging from inflammatory bowel disease (IBD) to colorectal cancer.
› Verified 5 days ago
Dr. Stephen E. Litsey, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2375 Champions Blvd, Auburn, AL 36830 Phone: 334-745-6447 | |
Alexus Briana Young, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2375 Champions Blvd, Auburn, AL 36830 Phone: 334-745-6447 | |
Mrs. Rajamalliga N Sharma, M.D., M.A. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2290 Moores Mill Rd, Suite 200, Auburn, AL 36830 Phone: 334-502-9888 Fax: 334-502-9190 | |
Dr. Robert Michael Marino, MD, MHA Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2375 Champions Blvd, Auburn, AL 36830 Phone: 334-745-6447 Fax: 334-742-0713 | |
Jonathan Mahram, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2375 Champions Blvd, Auburn, AL 36830 Phone: 334-745-6447 Fax: 334-742-0713 | |
Dr. William L. Golden, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2375 Champions Blvd, Auburn, AL 36830 Phone: 334-745-6447 Fax: 334-742-0713 | |
Caitlin Roach Spivey, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2375 Champions Blvd, Auburn, AL 36830 Phone: 334-745-6447 |